Cargando…

Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience

Vaccination against SARS-CoV-2 infection is currently approved and shows favorable outcomes, but little known about antibody responses in solid organ transplant recipients, since these patients are known to have an impaired immune response upon vaccination and have not been included in admission stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashidi-Alavijeh, Jassin, Frey, Alexandra, Passenberg, Moritz, Korth, Johannes, Zmudzinski, Jaqueline, Anastasiou, Olympia E., Saner, Fuat H., Jahn, Michael, Lange, Christian M., Willuweit, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310292/
https://www.ncbi.nlm.nih.gov/pubmed/34358154
http://dx.doi.org/10.3390/vaccines9070738
_version_ 1783728725388427264
author Rashidi-Alavijeh, Jassin
Frey, Alexandra
Passenberg, Moritz
Korth, Johannes
Zmudzinski, Jaqueline
Anastasiou, Olympia E.
Saner, Fuat H.
Jahn, Michael
Lange, Christian M.
Willuweit, Katharina
author_facet Rashidi-Alavijeh, Jassin
Frey, Alexandra
Passenberg, Moritz
Korth, Johannes
Zmudzinski, Jaqueline
Anastasiou, Olympia E.
Saner, Fuat H.
Jahn, Michael
Lange, Christian M.
Willuweit, Katharina
author_sort Rashidi-Alavijeh, Jassin
collection PubMed
description Vaccination against SARS-CoV-2 infection is currently approved and shows favorable outcomes, but little known about antibody responses in solid organ transplant recipients, since these patients are known to have an impaired immune response upon vaccination and have not been included in admission studies. We therefore analyzed immunogenicity in 43 liver transplant (LT) recipients in a median of 15 days (IQR, 12–24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers (HCWs). Thirty-four of the 43 (79%) LT recipients developed antibodies, compared to 20 out of 20 (100%) in the control group (p = 0.047). The median SARS-CoV-2 IgG titer was significantly lower in the LT recipients compared to the control group (216 vs. >2080 BAU/mL, p = 0.0001). Age and sex distribution was similar in the LT patients that developed antibodies after vaccination compared to those who did not. Interestingly, the patients who received mycophenolate mofetil exhibited a reduced vaccination response compared to the other LT patients (5 of 11 (45.5%) vs. 29 of 32 (90.6%), p = 0.004). In conclusion, our data reveal lower immunogenicity of SARS-CoV-2 vaccine BNT162b2 in LT patients compared to the control group, but still show superior results compared to other solid organ transplant recipients reported so far.
format Online
Article
Text
id pubmed-8310292
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83102922021-07-25 Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience Rashidi-Alavijeh, Jassin Frey, Alexandra Passenberg, Moritz Korth, Johannes Zmudzinski, Jaqueline Anastasiou, Olympia E. Saner, Fuat H. Jahn, Michael Lange, Christian M. Willuweit, Katharina Vaccines (Basel) Communication Vaccination against SARS-CoV-2 infection is currently approved and shows favorable outcomes, but little known about antibody responses in solid organ transplant recipients, since these patients are known to have an impaired immune response upon vaccination and have not been included in admission studies. We therefore analyzed immunogenicity in 43 liver transplant (LT) recipients in a median of 15 days (IQR, 12–24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers (HCWs). Thirty-four of the 43 (79%) LT recipients developed antibodies, compared to 20 out of 20 (100%) in the control group (p = 0.047). The median SARS-CoV-2 IgG titer was significantly lower in the LT recipients compared to the control group (216 vs. >2080 BAU/mL, p = 0.0001). Age and sex distribution was similar in the LT patients that developed antibodies after vaccination compared to those who did not. Interestingly, the patients who received mycophenolate mofetil exhibited a reduced vaccination response compared to the other LT patients (5 of 11 (45.5%) vs. 29 of 32 (90.6%), p = 0.004). In conclusion, our data reveal lower immunogenicity of SARS-CoV-2 vaccine BNT162b2 in LT patients compared to the control group, but still show superior results compared to other solid organ transplant recipients reported so far. MDPI 2021-07-04 /pmc/articles/PMC8310292/ /pubmed/34358154 http://dx.doi.org/10.3390/vaccines9070738 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Rashidi-Alavijeh, Jassin
Frey, Alexandra
Passenberg, Moritz
Korth, Johannes
Zmudzinski, Jaqueline
Anastasiou, Olympia E.
Saner, Fuat H.
Jahn, Michael
Lange, Christian M.
Willuweit, Katharina
Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title_full Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title_fullStr Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title_full_unstemmed Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title_short Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience
title_sort humoral response to sars-cov-2 vaccination in liver transplant recipients–a single-center experience
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310292/
https://www.ncbi.nlm.nih.gov/pubmed/34358154
http://dx.doi.org/10.3390/vaccines9070738
work_keys_str_mv AT rashidialavijehjassin humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT freyalexandra humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT passenbergmoritz humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT korthjohannes humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT zmudzinskijaqueline humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT anastasiouolympiae humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT sanerfuath humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT jahnmichael humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT langechristianm humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience
AT willuweitkatharina humoralresponsetosarscov2vaccinationinlivertransplantrecipientsasinglecenterexperience